Tocilizumab shows no significant benefit for patients with severe Covid-19 pneumonia

Health · Published 1 October 2026 Swipe more like this →

In short: A phase 3 randomized trial of 438 hospitalized patients found that the monoclonal antibody tocilizumab did not significantly improve clinical outcomes or reduce death rates compared to a placebo. The study focused on patients suffering from severe pneumonia caused by Covid-19, investigating whether blocking certain immune signals could alter the course of the disease.

Researchers randomly assigned participants to receive either a single intravenous infusion of tocilizumab or a placebo, with some receiving a second dose shortly after. While the drug targets interleukin-6 receptors to manage hyperinflammation, the results showed no significant difference in clinical status or mortality at 28 days. The study's findings are limited to the specific population of hospitalized patients with severe pneumonia.

Why it matters: Targeting interleukin-6 with tocilizumab did not improve survival or clinical recovery in this group of severe Covid-19 patients.

General information, not professional advice. Spotted an error? Flag the card or see corrections and complaints.

Intellect Plus is a visual educational discovery platform for exploring fascinating facts and ideas. Brain Food, Not Brain Rot. What is Intellect Plus?

Related

• Interleukin-6 receptor antagonists improve outcomes for critically ill Covid-19 patients
• Early antibody treatment significantly reduces hospitalization and death in high-risk Covid-19 patients
• Combination antibody treatment reduces viral load in mild to moderate COVID-19
• Vaccine efficacy against the B.1.351 variant appeared low in early clinical observations
• Lab tests show Delta variant partly evades vaccine- and infection-induced antibodies
• Vaccine protection against the Delta variant appeared to decline months after vaccination
• For COVID-19 screening, testing often and fast beats using the most sensitive test
• Could deliberately infecting volunteers save lives during a pandemic?
• Persistent neurological and neuropsychiatric symptoms are common features of long-term COVID-19
• How twelve historical plagues reshaped the trajectory of human civilization
• Oral antiviral molnupiravir reduces hospitalization and death risk for high-risk Covid-19 patients
• Omicron variant escapes much of the antibody protection from vaccines and prior infection

More in Pandemics & epidemics · More in Health · Latest · A–Z · All topics